期刊
CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 102, 期 3, 页码 520-528出版社
WILEY
DOI: 10.1002/cpt.664
关键词
-
资金
- National Institutes of Health (NIH) [4P01HD059454-09, R01AI117001]
- UCSF Center for AIDS Research [P30 AI022763]
Dihydroartemisinin (DHA)-piperaquine is promising formalaria chemoprevention in pregnancy. We assessed the impacts of pregnancy and efavirenz-based antiretroviral therapy on exposure to DHA and piperaquine in pregnant Ugandan women. Intensive sampling was performed at 28 weeks gestation in 31 HIV-uninfected pregnant women, in 27 HIV-infected pregnant women receiving efavirenz, and in 30 HIV-uninfected nonpregnant women. DHA peak concentration and area under the concentration time curve (AUC(0-8hr)) were 50% and 47% lower, respectively, and piperaquine AUC(0-21d) was 40% lower in pregnant women compared to nonpregnant women. DHA AUC(0-8hr) and piperaquine AUC(0-21d) were 27% and 38% lower, respectively, in pregnant women receiving efavirenz compared to HIV-uninfected pregnant women. Exposure to DHA and piperaquine were lower among pregnant women and particularly in women on efavirenz, suggesting a need for dose modifications. The study of modified dosing strategies for these populations is urgently needed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据